The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
In prostate cancer Clovis could be adopting a more realistic regulatory stance with its Parp than Astrazeneca and Merck & Co. In the long run will it matter much?
The rare disease bile duct cancer is set to be carved up by genetic subtype, and will see two targeted treatments filed soon.
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.